Status:
COMPLETED
Miltefosine Plus IL Pentamidine for Bolivian CL
Lead Sponsor:
Jonathan Berman
Conditions:
Leishmaniasis, Cutaneous
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days ...
Detailed Description
Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days ...
Eligibility Criteria
Inclusion
- one ulcerative lesion ≤ 900 mm2 in total area,
- ≥ 12 years,
- parasitologically diagnosed by visualization of amastigotes or culture of promastigotes from lesion material,
- no antileishmanial therapy in the last 3 months,
- no mucosal lesions,
- no history of significant concomitant diseases including immunosuppression.
Exclusion
Key Trial Info
Start Date :
January 31 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03445897
Start Date
January 31 2016
End Date
February 21 2018
Last Update
February 27 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.